Related Experiment Videos

Resistance to lipophilic cationic compounds in multidrug resistant leukemia cells

A Ramu1, N Ramu

  • 1Department of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Leukemia & Lymphoma
|February 1, 1993
PubMed

Insights

Multidrug resistant cells exhibit cross-resistance to permanently charged, lipophilic compounds. This resistance is linked to the compound's cationic charge, not its size or lipophilicity.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Cell Biology

Background:

  • Multidrug resistance (MDR) in cancer cells limits therapeutic efficacy.
  • MDR cells display cross-resistance to various chemotherapeutic agents.
  • Previous studies identified cross-resistance to certain permanently charged cationic lipophilic compounds.

Purpose of the Study:

  • To investigate cross-resistance in multidrug resistant P-388 murine leukemia cells.
  • To evaluate the growth inhibitory activity of novel triphenylalkyl-phosphonium and alkyl-ammonium compounds.
  • To determine the structural factors (charge, size, lipophilicity) influencing cross-resistance.

Main Methods:

  • Synthesis and testing of triphenylalkyl-phosphonium and alkyl-ammonium compounds.
  • Assessment of growth inhibitory activity against P-388 murine leukemia cells.
  • Correlation analysis of compound structure with observed resistance.

Main Results:

  • Multidrug resistant P-388 cells showed cross-resistance to tested phosphonium and ammonium compounds.
  • Cross-resistance was observed across compounds with unrelated chemical structures.
  • The presence of a cationic charge was identified as the key factor for cross-resistance.

Conclusions:

  • Cationic charge, rather than molecular size or lipophilicity, dictates cross-resistance in MDR cells.
  • These findings contribute to understanding MDR mechanisms.
  • Potential for developing new therapeutic strategies targeting MDR.

Related Concept Videos